We used [ lB F]fluorodeoxyglucose/positron emission tomography e B F-FDG/PET) and a statistical model of regional covariation to study brain topographic organization in parkinsonism. We studied 22 patients with Parkinson's disease (PD), 20 age-matched normal volun teers, and 10 age-and severity-matched patients with pre sumed striatonigral degeneration (SND). We used FDGI PET to calculate global, regional, and normalized meta bolic rates for glucose (GMR, rCMR g lc, rCMR g lc/GMR). Metabolic parameters in the three groups were compared using an analysis of variance, with a correction for mul tiple comparisons, and discriminant analysis. The scaled sub profile model (SSM) was applied to the combined rCMR g lc dataset to identify topographic covariance pro files that distinguish PD patients from SND patients and normals. GMR, rCMR g lc, and rCMR g lc/GMR were nor mal in PD; caudate and lentiform rCMR g lc/GMR was re duced in the SND group (p < 0.01). SSM analysis of the combined group of patients and normals revealed a sig nificant topographic profile characterized by increased
metabolic activity in the lentiform nucleus and thalamus associated with decreased activity in the lateral frontal, paracentral, inferior parietal, and parietooccipital areas. Individual subject scores for this profile were signifi cantly elevated in PD patients compared with normals and SND patients (p < 0.001) and discriminated the three groups. In the PD group, subject scores for this factor correlated with individual subject Hoehn and Yahr (H&Y) scores (p < 0.02), and with quantitative rigidity (p < 0.01) and bradykinesia (p < 0.03) ratings, but not with tremor ratings. SSM analysis of right-left metabolic asymmetries yielded a topographic contrast profile that accurately discriminated mildly affe cted PD patients (H&Y Stage I) from normals. Our findings demonstrate that abnormal topographic covariance profiles exist in parkinsonism. These profiles have potential clinical ap plication as neuroimaging markers in parkinsonism. Key Words: e B F]Fluorodeoxyglucose-Metabolic topogra phy-Parkinsonism-Positron emission tomography Striatonigral degeneration.
Although the primary biochemical pathology of Parkinson's disease (PD) is localized to the substan tia nigra and its dopaminergic projections (Bern heimer et aI., 1973) , lesions of the presynaptic ni grostriatal 3,4-dihydroxyphenylethylamine (dopa mine) system produce widespread abnormalities in regional cerebral metabolism and blood flow (Wooten and Collins, 1981; Crossman et aI., 1985 Crossman et aI., , 1990 Porrino et aI., 1987; Palombo et aI., 1990) . Studies in patients with PD using positron emission tomography (PET) have suggested increases in basal ganglion metabolism (Martin et aI.: 1984; Rougement et aI., 1984; Wolfson et aI., 1985; Eidel berg et aI., 1990) , as well as decreases in inferior parietal and global metabolism, especially in pa tients with dementia (Kuhl et aI., 1984; Peppard et aI., 1990; Schapiro et aI., 1993) . Nonetheless, re gional and global metabolic changes have not been fully reproducible across study populations, and the relationship of these metabolic changes to indepen dent indices of disease severity has not been closely examined.
It is generally recognized that many of the behav ioral manifestations of normal and pathological ner vous system function are subserved by topograph ically distributed networks of interacting brain re gions (e. g. , Mesulam, 1981) . These networks may be r epresented as patterns of covariation among spatially distributed brain regions and can be al tered by behavioral activation or the presence of disease. Specifically, normal regional covariance patterns may be disrupted by the presence of local ized pathology such as that occurring in neurode generative disorders such as Alzheimer's disease and PD. Several approaches have evolved to iden tify and quantify these regional interactions. Princi pal-components analysis (peA) has been used in the analysis of PET data to contrast groups in the same resting state (e.g. , Moeller et aI. , 1987; Rot tenberg et aI. , 1987; Eidelberg et aI. , 1990; Sackeim et aI. , 1990) and, more recently, in brain activation paradigms (McLaughlin et aI. , 1992; Friston et aI. , 1993) . peAs extract multiple independent compo nents that, singly or in combination, account for the majority of the variance in the regional PET data.
These principal components or topographic co variance profiles can be construed as distributed neural networks. The scaled subprofile model (SSM), described by us previously (Moeller et aI. , 1987 ; Moeller and Strother, 1991) , applies peA to combined populations of subjects (e. g. , patients and normal control subjects) blind to subject groupings. SSM extracts those principal components across which there is maximal regional variability. Each topographic profile is associated with an individual subject score that quantifies the extent to which the topographic profile is manifested by the subject. SSM analyses have been applied previously to func tional imaging data from a variety of neurodegener ative and psychiatric disorders (Rottenberg et aI. , 1987 ; Anderson et aI. , 1988; Eidelberg et aI. , 1990; Sackeim et aI. , 1990 Sackeim et aI. , , 1993 .
In a preliminary attempt to identify abnormal re gional covariation patterns in PD, we reported an SSM analysis of e S F]fluorodeoxyglucose (FDG) PET data from 14 patients with PD and 18 normal control subjects (Eidelberg et aI. , 1990) . The results suggested the presence in PD of abnormal topo graphic profiles characterized by covarying basal ganglia and thalamic increases in metabolism, most evident in an analysis of right-left metabolic asym metries. Individual subject scores for these profiles correlated significantly with independent measures of disease severity and with striatal e S F]fluoro-3,4-J Cereb Blood Flow Metab, Vol. 14, No. 5, 1994 dihydroxyphenylalanine (FDOPA) uptake rate con stants. This study was limited by the low resolution of the PET tomograph, and basal ganglia metabolic activity could not be subdivided into smaller subre gions, such as the caudate and lentiform nuclei. In addition, several of the patients with PD received levodopa at the time of the PET study and the nor mal control subjects were not age-matched.
In this study we sought to validate and expand upon the previous findings by examining FDG/PET data derived from a larger, entirely new cohort of medication-free PD patients and age-matched con trols using a higher-resolution tomograph. Topo graphic profiles from the new population were com pared with those derived previously. To assess the potential of these profiles to serve as disease specific markers, we correlated the individual sub ject profile weights with independent clinical ratings across a broad range of disease severity. We also explored the potential for early disease detection by performing discriminant analyses between normals and patients at a stage of mild, early disease.
Another aim was to explore the broader applica tion of SSM in functional imaging studies of the akinetic-rigid movement disorders. We have re ported previously that striatonigral degeneration (SND) (Adams et aI. , 1964) , a parkinsonian syn drome clinically resembling PD (Fearnley and Lees, 1990) , is associated with basal ganglia hypometab olism, which distinguishes it from its classical drug responsive counterpart (Eidelberg et aI. , 1993) . By adding a sample of patients with SND to a com bined sample of age-matched normal control sub jects and age-and severity-matched patients with PD, we sought to determine whether SND was as sociated with a different topographic profile than PD or whether the same topographic profiles were affected in both parkinsonian disorders. In addition, this three-group analysis allowed us to explore the applicability of SSM analyses in the differential di agnosis of clinically similar but pathologically dis crete neurodegenerative disorders.
MATERIALS AND METHODS

Subjects
The fo llowing subject groups were studied with quan titative FDGIPET.
Normal Subjects. We studied 20 normal volunteer sub jects (10 men and 10 women; mean age ± SD, 47.0 ± 17.1 years) recruited by advertisement among the hospital per sonnel of North Shore University Hospital/Cornell Uni versity Medical College and the spouses of PD patients in local support groups. The following exclusion criteria were used: (a) a history of neurological or psychiatric illness; (b) prior exposure to neuroleptic agents or drug use; (c) a medical history of hypertension, cardiovascular disease, and diabetes mellitus; and (d) an abnormal neu rological examination.
Patients with PD. We studied 22 idiopathic PD patients without dementia (12 men and 10 women; age, 57.9 ± 11.4 years). A diagnosis of PD was made if the patient had "pure" parkinsonism without a history of known caus ative factors such as encephalitis or neuroleptic treat ment; did not have early dementia, supranuclear gaze ab normalities, or ataxia; and did have a convincing re sponse to levodopa [�20% change in composite Unified Parkinson Disease Rating Scale (UPDRS) 3.0 motor scores (items 19-31) (Fahn et aI., 1987) ]. In all patients family histories were negative for neurodegenerative ill nesses. Magnetic resonance imaging (MRI) was per formed in 18 of 22 patients and computed tomography (CT) scanning in 4 of 22 patients. High-field strength T2weighted MRI (echo time, �80 ms; repetition time, �1,500 ms; field strength, �1.0 T) disclosed a normal putamenal signal in all cases studied. Visually evident cortical or subcortical atrophy was absent in all patients.
Patients were selected with a range of clinical severity according to their Hoehn and Yahr (H&Y) (1967) ratings. Five patients were selected in each of H&Y Stages I-IV and two patients in H& Y Stage V. (Patient representation in the latter category was limited by the technical diffi culty associated with scanning markedly disabled ad vanced patients.) To facilitate comparisons between mild and moderate-severe patients, the PD group was subdi vided into two subgroups (Table 1) : The mild group (PD1: H&Y Stages I-II) consisted of 10 patients (5 men and 5 women; age, 53.0 ± 9.9 years; mean disease duration, 4.4 ± 3.0 years). The advanced group (PD2: H&Y Stages III-V) consisted of 12 patients (7 men and 5 women; age, 61.9 ± 11.2 years; mean disease duration, 11.5 ± 6.1 years). The clinical characteristics of these PD patients are given in Table 1 .
Patients with SND. We studied 10 patients (8 women and 2 men; age, 61.8 ± 6.9 years) with clinical findings compatible with SND (Fearnley and Lees, 1990) . The clinical characteristics of these 10 SND patients and their case histories have been reported by us elsewhere (Eidel berg et aI., 1993) . All patients presented with progressive limb rigidity and bradykinesia associated with early im pairment of balance and gait and without ataxia, supra nuclear gaze abnormalities, or dementia. Motor symp toms were refractory to levodopa and dopamine agonists (daily dose, �1,000 mg levodopa equivalents; :;;; 15% change in composite UPDRS motor scores). Transient or minimal levodopa responses were evident in four of these patients. Six of the SND patients were on chronic levo dopa therapy up to the time of PET imaging; the remain der were off medication for at least 2 weeks prior to scan ning. MRI was performed on eight patients and CT on two patients. High-field strength T2-weighted MRI (echo time, �80 ms; repetition time, �1,500 ms; field strength, � 1.0 T) disclosed patchy putamenal loss of signal in four of eight patients. Mild brain-stem atrophy was noted in one patient; cortical atrophy was absent in all patients. Metabolic data on the 10 SND patients, 15 of 22 PD pa tients, and 10 of20 normal subjects have been reported by us previously (Eidelberg et aI., 1993) .
PET
The patients and volunteers fasted overnight prior to FDGIPET scanning. In all PD and SND patients, all an tiparkinsonian medications were discontinued at least 12 h before PET was conducted. At the time of PET study, all PD and SND patients were rated quantitatively ac- cording to the H&Y and UPDRS scales. PET studies were performed using the Superpett 3000 tomograph (Scanditronix; Essex, MA, U.S.A.). The performance characteristics of this instrument have been described elsewhere (Robeson et aI., 1993) . This four-ring BaF2 time-of-flight, whole-body tomograph acquires 14 PET slices with Z-axis translation. Each slice is 8 mm thick and reconstructed with a transaxial resolution of 8 mm (full width at half-maximum). Ethical permission for these studies was obtained from the Institutional Review Board of North Shore University Hospital/Cornell University Medical College. Written consent was obtained from each subject following a detailed explanation of the proce dures.
PD patients
Patients were positioned in the scanner in a custom molded headrest (Alpha Cradle; Smithers Medical, Tall madge, OH, U.S.A.) (Kearfott, 1984) with three dimensional laser alignment with reference to the orbito meatal (OM) line. A cylindrical tube filled with 68 Ge was placed in the field of view to provide internal calibration for each slice. All studies were performed with the sub ject's eyes open in a dimly lit room and minimal auditory stimulation. FDG was produced using the radiochemical synthesis of Chaly and colleagues (1990) . Subjects re ceived 5-10 mCi of FDG by intravenous injection. The time course of plasma 18 F radioactivity was determined by sampling radial arterial blood followed by centrifuga tion. PET images were reconstructed with a correction for tissue attenuation of 511 ke V of 'Y radiation measured with an external 68 Ge ring source. PET reconstructions were also corrected for random coincidences, electronic dead time, and tissue attenuation. A single scalar correc tion was used to compensate for scatter effects in trans mission, cross-calibration, and emission scans (Robeson et aI., 1993) .
We calculated global and regional metabolic rates for glucose (GMR and rCMR g lc, respectively) in all FDGI PET studies using autoradiographic scans (Phelps et aI., 1979) acquired for 20 min beginning 35 min postinjection, with estimated mean normal rate constants [k1 = 0.1056, k2 = 0.1584, k3 = 0.0904; k4 was fixed at 0.0068 (Dhawan et aI., 1989; Eidelberg et aI., 1993; Robeson et aI., 1993) ]. To facilitate comparisons with our previous metabolic data, we chose a lumped constant of 0.42.
Region-of-interest (ROI) analysis was performed on 256 x 256 PET reconstructions using a SUN microcom puter (490 SPARC Server; Sun Microsystems, Mountain View, CA, U.S.A.) with ScaniVP Software (Spetsieris et aI., 1993) . To compare regional values with those re ported by us earlier (Eidelberg et aI., 1990 (Eidelberg et aI., , 1993 , we defined 26 (13 per hemisphere) standardized cortical and subcortical gray matter ROIs and two cerebellar and two brain-stem ROIs. ROIs were defined interactively on re constructed PET slices by visual inspection with refer ence to a standard neuroanatomical atlas (Talairach and Tournoux, 1988) and MRI or CT when available. Mean ROI size ranged from 40 pixels for the caudate nucleus to 350 pixels for the lateral frontal and temporal cortical regions (1 pixel = 4 mm 2 ). To reduce partial volume ef fe cts, we calculated "peak" rCMR g lc values by averaging the upper 20% of ROI pixel values (Rottenberg et aI., 1991) . Whenever anatomical regions straddled contiguous PET slices, the rCMR g lc was calculated by weighting component ROI values by the number of thresholded pix els on each slice. The GMR was calculated as the mean of the rCMR g lc values weighted by the total number of J Cereb Blood Flow Metab, Vol. 14, No. 5, 1994 thresholded pixels in each ROI. To reduce intersubject variability, regional metabolic measurements were nor malized by global values (rCMR g lc/GMR). We also calcu lated a right-left asymmetry index (orCMR g lc) for each paired region defined as (L -R)/(L + R) x 100%, where L and R refer to left and right homologous rCMR g lc val ues, respectively.
Statistical analyses
Glucose Metabolism. The following statistical proce dures were employed for between-group comparisons. (a) We compared GMR and rCMR g lc and GMR-normalized regional values (rCMR g lc/GMR) for the various clinical groups using analysis of variance (ANOV A) followed by post hoc group comparisons using the Tukey-Kramer HSD adjustment (Winer, 1971) . This procedure was ap plied separately to all the individual regional values (30 rCMR g ic and 30 rCMR g lc/GMR measurements) and to the GMR. (b) To identify the regional values that maximally discriminate the various groups, we employed stepwise discriminant analysis using the F test associated with Wilks' A (Anderson, 1984) . The p values are reported incorporating the Bonferroni correction for the number of regional comparisons. Differences between groups were considered significant when comparisons exceeded 95% confidence limits (p < 0.05).
In this study we performed two separate sets of be tween-group comparisons: In the first analysis, we com pared the metabolic parameters derived for the entire typ ical PD (n = 22) and normal control (n = 20) samples. In the second analysis, we performed a three-group compar ison of the metabolic parameters measured in the entire SND sample (n = 10; mean age, 61.8 ± 6.9 years; mean H&Y score, 3.5 ± 0.8), an age-and severity-matched subset of the PD2 sample (Patients 11-18, 22, and 23; n = 10; mean age, 60.6 ± 10.8 years; mean H&Y score, 3.7 ± 0.8), and an approximately age-matched normal control samples (n = 10; mean age, 57.6 ± 12.6 years). Identical statistical procedures were carried out for each set of between-group comparisons.
SSM: Methodology. To determine whether specific patterns of regional metabolic covariation distinguished the groups, patient and normal control rCMR g lc datasets were analyzed using SSM. The mathematical properties of this model, its statistical assumptions, and its compu tational procedures have been described elsewhere (Moeller et aI., 1987; Moeller and Strother, 1991; Sackeim et aI., 1993 ). This statistical model proposes that, for each subject, each regional rCMR g lc value is comprised of two basic elements. (a) A diffuse or regional-independent scaling factor (global scaling factor; GSF) modulates or scales all regional values for a given individual. The GSF is similar to the GMR, but the contributions of the topo graphic profiles are removed in the calculation of the GSF. (b) Independent sets of topographic profiles corre spond to different patterns of covariance among brain regions. The contribution of a particular brain region to a topographic profile, i.e., its relative importance in the covariance relationships within the profile, is quantified by its regional weight in the corresponding top o graphic profile. Therefore, the topographic profile is a vector of regional values representing the covariance relationships among the brain regions. Because different individuals manifest these relationships to greater or lesser degrees, the SSM computes a subject score (subject scaling factor; SSF) to quantify individual differences in manifesting each topographic profile.
All SSM parameters were derived by applying the model to the data from the total sample, blind to group membership. The computations involved subtracting from each subject' s regional values the mean value at each region, determined across the total sample. These difference scores produced the approximation to the sub ject x region variance. A PCA was performed on the transposed covariance matrix of these difference scores to extract a set of principal (unrotated) components. The region weights on each principal component described a topographic covariance profile. The subject scores for a principal component (PCA scalars or SSFs) quantified the extent to which the topographic pattern was manifested by the individual subject. The number of principal com ponents to retain was determined by applying the Scree test (Stevens, 1986) to the set of eigenvalues and by ex amining the extent to which the SSFs accounted for the variance in GMR values. The GSF was computed for each subject using multiple regression analysis to predict global mean rCMR g lc values on the basis of the SSFs. The GSF corresponded to the residual between predicted and obtained values. Adding the intercept term to the residu als produced the final form of the GSF in the original rCMR g lc units.
In addition, a separate analysis of right-left metabolic asymmetries was performed using the orCMR g Jc meta bolic asymmetry measures. This procedure is computa tionally identical to the SSM analysis of the hemispheric rCMR g ic data described above. However, by using orCMR g lC values, this SSM analysis identifies topo graphic contrast profiles representing covariance patterns of regional metabolic asymmetry whose contribution may vary across the subjects analyzed within the total sample.
To determine whether the groups diffe red on the SSM parameters of GMR (GSF) or topographic organization (SSFs), the same ANOV A procedures and discriminant analyses were applied as described above for the rCMR g lc datum analysis. The p values were corrected for multiple SSF and GSF comparisons using an ordered Bonferroni procedure with ranking by eigenvalue (Rosenthal and Ru bin, 1984) .
SSM: Clinical Correlations and Topographic Profile Comparisons. Clinical-metabolic correlations. Pearson product-moment correlations were computed to examine the relationship between the clinical and the metabolic measures. The following clinical parameters were used in these correlations: H&Y scores, individual UPDRS mo tor scores for tremor, rigidity, bradykinesia, posture, and gait, and a composite motor score defined as the sum of items 19-31 in the UPDRS (Fahn et aI., 1987) . We also calculated a limb asymmetry index defined by right-left differences in individual limb UPDRS scores (Eidelberg et aI., 1990) . Because these clinical scores may be closely correlated within individual subjects, we performed a pairwise correlational analysis of the individual scores to identify interrelated subsets of scores (Eidelberg et aI., 1990) . H&Y scores, composite UPDRS motor scores, mean values of intercorrelated subsets of scores, and in dividual UPDRS scores were correlated with the follow ing metabolic measures: (a) rCMR g Jc and rCMR g lc/GMR for all 30 right-and left-hemispheric and brain-stem ROIs; (b) SSFs for the various topographic profiles; and (c) the global metabolic measures, GMR and GSF. The p values were corrected for the number of independent clinical-metabolic correlations performed and were considered significant when <0.05.
Topographic profile comparisons. Reproducibility. We compared the results of this SSM analysis to those de scribed by us in an earlier analysis of an entirely different sample of PD patients and normal control subjects (Ei delberg et aI., 1990) . Specifically, we performed separate SSM analyses of combined rCMR g lC data from the normal controls and PD patients comprising each of the two study populations. Region weights on the individual to pographic profiles derived in the two analyses were com pared using correlation analysis.
Comparison of parkinsonian subtypes. To explore the potential applicability of SSM in the differential diagnosis of clinically similar but pathologically discrete movement disorders, we performed this procedure on rCMR g Jc data fr om a combined three-group cohort containing the 10 SND patients, the 10 age-and severity-matched PD2 pa tients, and 10 age-matched normal subjects (n = 30). This analysis allowed us to determine (a) whether including SND patients in the SSM analysis introduced a new to pographic profile that was not evident in the original two group analysis of the fu ll normal control and PD cohorts (n = 42), (b) whether the same topographic profiles ex tracted previously were also identifiable in this three group analysis, and (c) whether SND patients can be dif fe rentiated from PD counterparts of similar age and dis ease severity based upon subject scores for one or more of the topographic profiles identified in the SSM analysis. To address these questions, we used correlation analysis to compare the region weights on the topographic profiles identified in the three-group analysis with the correspond ing regional values derived in the original two-group anal ysis. Similarly, SSF values for the various topographic profiles derived in the two sets of between-group analyses were correlated in the 20 subjects (10 PD patients and 10 normal subjects) common to both analyses. GSF and SSF values for the three groups included in this SSM analysis were compared using the ANOV A procedures and dis criminant analyses described above. All statistical analy ses were carried out using SAS (SAS Institute, Cary, NC, U.S.A.).
RESULTS
Glucose metabolism
Mean rCMRglc/GMR and GMR values for the PD, SND, and normal control groups are given in Ta ble 2. In the SND group, caudate and lentiform rCMRglc/GMR values were significantly reduced compared with those of age-matched normals and age-and severity-matched PD patients (p < 0.01).
The parkinsonian groups did not differ from the nor mals in any other measure of regional or global me tabolism (p > 0.05 for all comparisons).
SSM: topographic profiles
SSM analysis of the rCMRglc data from the com bined group (n = 42) disclosed three significant to pographic profiles that accounted for 47. 1 % of the subject ox region variance. Individual differences in manifesting these three topographic profiles (SSFs) accounted for 43 .7% of the variance in GMR. This indicated that a substantial portion of GMR vari ability was due to individual differences in these major topographic effects. When the topographic effects were removed, a region-independent global measure (GSF) was calculated. The PD and normal groups did not differ in GSF, suggesting that the two groups differ primarily in the representation of the topographic profiles. The region weights on the three significant topo graphic profiles are presented in Table 3 . SSF val-ues for the various profiles were z-transformed and offset to a mean of zero for the normal control pop ulation. (Scalar adjustments in subject scores do not influence between-group statistical comparisons or clinical correlations because all members of the samples are shifted equally.) Thus, individual SSFs were interpreted relative to an adjusted metabolic baseline defined by the normal control population. Additionally, the polarity of the profiles was ori ented so that the mean SSFs for the PD group had positive values and positive subject x region pro- The topographic profiles were identified by SSM analysis of bihemispheric rCMRglc data from a combined group of 22 PD patients and 20 normal control subjects. Positive and negative values indicate regions of relative metabolic increases and decreases, respectively. Region weights ;;.1 are italicized; those also associated with motor control networks are boldfaced. Med., medial ; lat., lateral ; sup., superior; inf., inferior. files Sackeim et aI., 1993) .
The following topographic profiles were identi fied in the analysis of bihemispheric rCMR g Jc data (n = 42):
Topographic Profile 1. This topographic profile (20.7% variance accounted for; V AF) was charac terized by increased activity of the cerebellum, pons, lentiform nucleus, and thalamus associated with covariate decreased activity of the lateral fron tal, paracentral, and parietal association cortices. (Calcarine activity did not contribute to this covari ance pattern, defining a reference point with which to compare the activity of the other regions.) An isometric display of this pattern is presented in Fig.  1 . Subject scores for this profile (SSF I) were signif icantly higher for the entire PD group compared with the normals (p < 0.001). The mean SSF1 was significantly higher in the PD2 subgroup compared with the PDI subgroup and the normal controls (p < 0.01 for both comparisons) (Fig. 2) . SSF1 discrimi nated the PD group from the normals [F(1,40) = 14.9, p < 0.001], specifically separating the ad vanced PD2 subset [PD1 vs. normal, F(1,28) = 1.1, nonsignificant; PD2 vs. normal, F(1, 30) = 36.0, p < 0.0002].
Topographic Profile 2. This topographic profile (15.9% VAF) was characterized by increased activ ity in the calcarine cortex and in the inferior parietal and parietooccipital areas. This was associated with decreased activity of the midbrain and medial and lateral temporal areas. Mean subject scores for this profile (SSF2) did not differ between or discriminate the PD and the normal groups.
Topographic Profile 3. This topographic profile (10.4% V AF) was characterized primarily by de creases in medial frontal and paracentral activity associated with increased parietooccipital and tem poral lobe activity. Mean SSF 3 values did not differ in the two groups.
The following topographic contrast profiles (Ta ble 4) were identified in the analysis of the regional asymmetry (8rCMRgJc) data (n = 42) .
Contrast profile 1. This contrast profile (14.0% V AF) was characterized by thalamic asymmetries covarying with reciprocal polarity with asymme tries in the paracentral cortex. Mean subject weights for this contrast profile (SSFcl) were signif icantly higher than normal for the H&Y Stage I pa tients (p < 0.02) but not for PD patients with more advanced disease (Fig. 3) . Contrast profile 2. This contrast profile (9.6% V AF) was characterized by thalamic and lentiform asymmetries covarying with reciprocal polarity with asymmetries in the caudate nucleus. Mean subject weights for this contrast profile (SSF d did not differ or discriminate among the normal and PD groups.
SSM: clinical correlations and topographic profile comparisons
Clinical-Metabolic Correlations. Glucose metab olism. Correlation analysis of PD clinical scores re vealed a strong pairwise correlation (r > 0.6, p < 0.001) between individual UPDRS scores for bradykinesia, rigidity, and gait, composite UPDRS motor ratings, and H&Y scores. Tremor ratings were not significantly associated with these other ratings (r < 0.32). We therefore considered brady kinesia, rigidity, and gait UPDRS scores to repre sent a discrete subset of interrelated clinical ratings, designated subset A. In the PD group, GMR corre lated negatively with H&Y scores (r = -0.58, p < 0.01), composite UPDRS motor ratings (r = -0.56, p < 0.01), subset A mean ratings (r = -0.60, p < 0.01), and individual UPDRS ratings for bradykine sia (r = -0.63, p < 0.005) and rigidity (r = -0.52, p < 0.05). GMR did not correlate with ratings for tremor, patient age, or disease duration (p > 0.1 for all correlations). In the PD group, regional meta bolic measures (rCMRgI C and rCMRgJc/GMR) did not correlate with age, H&Y scores, or any of the individual or composite ratings comprising the UPDRS (p > 0.1 for all correlations). SSM descriptors. In the PD group, GSF failed to correlate with clinical severity measures. This sug gests that the GMR correlations were due primarily to the contribution of topographic rather than global effects. In PD patients, SSF 1 correlated signifi cantly with age (r = 0.49, p < 0.04), H&Y ratings (r = 0.61, p < 0.02), composite UPDRS motor ratings (r = 0.56, p < 0.03), and subset A mean ratings (r = 0.63, p < 0.01), as well as with individual UPDRS ratings for bradykinesia (r = 0.56, p < 0.03) and rigidity (r = 0.62, p < 0.01) (Fig. 4) . No correlation was evident between SSF1 values and tremor rat ings (r = 0.06) or disease duration (r = 0.38). Nei ther SSF2 nor SSF3 values correlated with any of the clinical measures (p > 0.2 for all correlations).
SSFc2 values, obtained from the asymmetries anal ysis, correlated with limb asymmetry scores (r = -0.53, p < 0.04). SSF C I values did not correlate with this parameter. Topographic Profile Comparisons. Reproducibil ity. To examine the reproducibility of these topo graphic profiles across study populations, we cor related the region weights on these patterns with those derived in our earlier study of a different group of PD patients and normal controls (Eidel berg et al., 1990) . Each of the three major topo graphic profiles derived from bihemisphere analysis was highly correlated between the two study popu- . This indi cates that the reported bihemispheric topographic profiles are reproducible in different PD patient populations under varying tomographic imaging conditions. Of the two significant topographic con trast patterns derived through asymmetries analy ses, Contrast Profile 1 alone was correlated in the The topographic contrast profiles were identified by SSM anal ysis of 8rCMRglc data from a combined group of 22 PD patients and 20 normal control subjects. Positive and negative values indicate the relative laterality of the regional metabolic asymme tries (see text). Region weights :;;. 1 are italicized; those also as sociated with motor control networks are boldfaced. Med., me dial ; lat., lateral ; sup., superior; inf., inferior.
two datasets (r = 0.71, p < 0.01). Contrast Profile 2 in the current study did not correlate with the asymmetries profiles extracted in the earlier data set.
Comparison of parkinsonian SUbtypes. SSM anal ysis of a combined group of 10 SND patients, 10 age-and severity-matched PD patients, and 10 age matched normal controls revealed three significant topographic profiles accounting for 57.6% of the subject x region variance. Neither of the global met abolic measures, GMR or GSF, differed among the three groups (p > 0.3 for all comparisons). Region weights on the three major topographic profiles were highly correlated with region weights on the corresponding three profiles identified in the two group analysis (Topographic Profile 1, r = 0.76, p < 0.0001; Topographic Profile 2, r = 0. 86, p < 0.0001; Topographic Profile 3, r = 0. 49, p < 0.005). Simi larly, SSFs for these three profiles were highly cor related with values calculated for the same subjects examined in the two-group analysis (SSF I' r = 0.73, p < 0.0005 ; SSF2, r = 0.88, p < 0.0001; SSF3, r = 0.66, p < 0.002). Thus, the addition of a second distinct parkinsonian group to the SSM analysis did not introduce a new major topographic profile, nor did it distort the topography of the PD-associated profiles described above. Figure 5 displays the SSF values for each of the three topographic profiles identified in the com bined three-group analysis comprising the PD, SND, and normal control groups. Comparison of the SSFs for the three groups indicated that PD and J Cereb Blood Flow Me/ab, Vol. 14, No. 5, 1994 SND differed from one another in the polarity and magnitude of representation of these profiles. SSF 1 values were significantly greater in the PD group compared to the SND group (p < 0.001). SSF1 dis criminated the two parkinsonian groups [F(1, 18) = 32. 2, p < 0.0002], correctly identifying 9 of 10 pa tients in each of the PD and SND clinical catego ries. Mean SSF2 values did not differ in the three groups. Mean SSF3 values were not significantly different in the PD and SND groups. Without Bon ferroni correction for mUltiple SSF comparisons, we noted an abnormal elevation of SSF3 values in the SND group (p = 0.03), with a trend toward an abnormal elevation (p = 0.06) in the PD2 group.
These SSF3 abnormalities did not reach significance with Bonferroni correction.
DISCUSSION
In this report we demonstrate the utility of PCA approaches, specifically SSM, in the analysis of combined regional metabolic data from PD patients and normal controls. We found a reproducible, dis tinctive set of topographic covariance profiles that correlated with independent clinical measures of disease severity. In the subsequent discussion, we explore the interpretation of these topographic pro files in the context of the neuroanatomical networks relating to motor control, as well as their potential applicability in clinical research.
The metabolic anatomy of parkinsonism
In this study of PD, SSM analysis revealed a ma jor covariance profile (Topographic Profile 1) that was defined topographically by the key neuroana tomical elements of the motor control system. This profile was characterized by large positive region weights for the lentiform nucleus, thalamus, pons, and cerebellum and large negative region weights for the lateral frontal, paracentral, and parietal as sociation areas. The occipital cortex, a "neutral" brain region uninvolved in the disease process (Gibb, 1992) , had region weights nearest zero and, therefore, became a convenient reference point for the other regional values. The region weights on each topographic profile, multiplied by the associ ated SSF, constitute the contribution of the profile to overall normalized brain metabolism. Therefore, the region weights for Topographic Profile 1 may be interpreted as metabolic increases or decreases rel ative to the occipital baseline.
The finding of increased metabolism in th e lenti form nucleus and thalamus in PD is consistent with prior reports from experimental animal models of parkinsonism. In e 4 C]-2-deoxyglucose autoradio graphic experiments, unilateral nigrostriatal lesions " : 1 ·· �. "·l ·"·"· ·"·"·""·""" & · f: (;
give rise to increased rCMRglc in the ipsilateral globus pallidus (Kozlowski and Marshall, 1980; Wooten and Collins, 1981; Crossman et aI., 1985; Palombo et aI., 1990; Mitchell et aI., 1992) . Meta bolic change in the corpus striatum has been less consistent, suggesting either unchanged (Wooten and Collins, 1981; Mitchell et aI., 1992) , decreased (Kozlowski and Marshall, 1980; Schwartzmann et aI., 1993) , or increased (Palombo et aI., 1990) rCMRglc on the lesioned side. Increased metabolism in the ventral thalamus has been a consistent finding (Kozlowski and Marshall, 1980; Crossman et aI., 1985; Palombo et aI., 1990; Schwartzmann et aI., 1993) . These findings have been considered as re flecting the release of the basal ganglia from nigral dopaminergic inhibition. Specifically, the loss of in hibitory nigrostriatal dopaminergic projections re sults in functional overaction of the putamen, with a consequent increase in the firing of inhibitory af ferents to the lateral pallidum. As rCMR g lc is determined primarily by afferent synaptic activity Aucker et aI., 1983) , it is expected that lateral pal lidal metabolism should increase. The reduction in inhibitory afferents to the subthalamic nucleus (STH) from the LGP results in decreased STH me tabolism-in the face of increased neuronal activity in that region. STH excitatory projections to the medial pallidum (MGP) thereby increase, resulting in increased MGP metabolism. Similarly, inhibitory projections from the MGP to the ventral thalamus also increase, resulting in increased metabolism in these thalamic structures as well. The striking regional abnormalities demonstrated by autoradiography in experimental animal models may be obscured in lower-resolution human PET studies. A number of early PET studies demon strated hemispheric asymmetries in basal ganglion metabolism, with a bias toward metabolic increases contralateral to the clinically more affected limbs (Martin et aI., 1984; Wolfson et aI., 1985) . Localized basal ganglion hypermetabolism in bilaterally af fected individuals was not consistently evident in earlier PET studies (Kuhl et aI., 1984; Rougement et aI., 1984) but has been reported using modern to mographs of improved resolution (Blesa et al., 1991) .
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The inconsistencies in previous FDG/PET stud ies may stem from inherent difficulty in extracting quantitative measures of pallidal metabolism from the larger lentiform ROI. Indeed, because of the necessary spatial inclusion of the less consistently affected putamen, pallidal hypermetabolism may become obscured within the composite lentiform regional measurement. Lentiform hypermetabolism may therefore be low in absolute terms and may not be detectable using conventional statistical method ologies. Additionally, our inability to quantify pall idal rCMR g ic precisely may obscure possible clini cal-metabolic relationships that might exist be tween this measure and tremor (Perlmutter and Raichle, 1985) .
Apart from the inherent physical limitations of PET in the measurement of rCMRgJc in small re gions (Mazziotta et aI., 1981) , PET datum analysis requires statistical consideration of the mUltiplicity of regional measurements compared between groups (Winer, 1971) . In this report we have treated the individual rCMR g Jc and rCMR gJc/GMR mea sures as independent observations and have cor rected the associated p values accordingly. In keep ing with our earlier observations (Eidelberg et aI., 1990) , we found no significant differences in rCMR g Jc and rCMR g 1c/GMR between the PD and the normal groups and no significant clinical corre lations with these variables, even without imple menting the stringent Bonferroni correction. None theless, we are cognizant of the effects of interre gional covariation in PET data and have developed SSM as a means of quantifying these regional inter actions (Moeller et aI., 1987) . SSM analysis thus provides an alternative to traditional statistical ap proaches for the identification of small biologically relevant signals (Sackeim et aI., 1993) . By delineat ing independent topographic profiles, SSM tech niques can extract covariate functional elements within anatomically large and functionally hetero geneous ROIs. We associate the covariate lentiform and thalamic hyperfunction identified in Topo graphic Profile 1 with the hypermetabolism of the pallidum and ventral thalamus demonstrated in the auto radiographic animal experiments.
In addition to the basal ganglion-thalamus inter action, this topographic profile included abnormal covariate interactions of the cerebellum and pons. These two interconnected structures, with the thal amus, constitute a separate motor control system operating in parallel to the basal ganglion circuits (Brodal, 1981) . Indeed, these two systems share a common output to the primary and supplementary cortical motor areas. Although lesions of the pons and cerebellum have not been demonstrated histo pathologically in PD, these regions have been im plicated in experimental rodent models of 1-methyl-4-phenyl-l ,2,3 ,6-tetrahydropyridine neurotoxicity (Takada et aI., 1993) . In addition, these regions may be abnormally activated in the course of parkinso nian tremor (Brooks et aI., 1992) . Our data indicate that subject scores for Topographic Profile 1 did not correlate with resting-state tremor and that ponto cerebellar hypermetabolism can contribute to ab normal brain topography in both tremulous and atremulous PD patients. An SSM analysis compar ing PD patients with and without tremor may be helpful in determining whether the pontocerebellar hypometabolism evident in Topographic Profile 1 is part of a discrete tremor-specific network or wheth er it is a fragment of a more generalized disease related pattern.
Both basal ganglion and cerebellar subcortical motor systems exert their influence by modifying the activity of the cortical motor areas. Indeed, To pographic Profile 1 identified hypofunction of sev eral cortical regions involved in motor control. Nonetheless, primary, premotor, and supplemental motor ROIs could not be accurately specified. Be cause of intersubject variability in the cerebral con volutions and their relationship to local cytoarchi tecture (e.g., Le Gros Clark, 1945; Eidelberg and Galaburda, 1984; Rademacher et aI., 1993) , as well as potential focal atrophy effects, deformations into a common coordinate space (e.g., Fox et aI., 1988) may be inherently imprecise, especially without in dividual subject activation data. Three-dimensional MRI/PET coregistration may be somewhat more re liable for primary sensorimotor localization (e.g., Grafton et aI., 1991) but remains inexact for the supplementary motor area (SMA), which is not con sistently defined by sulcal markings. To preserve correspondence with the regional information de rived in our previous study, we opted for similarly large ROIs. Comparison with standard anatomical (Eycleshymer and Schoemaker, 1911) , architec tonic (von Economo, 1992) , and functional stereo tactic (Talairach and Tournoux, 1988 ) atlases re veals the lateral frontal ROI to be composed largely of elements of the lateral premo tor cortex and the frontal eye fields [areas 6 and 8 of Brodmann (von Economo, 1929) ]. [The pixel contribution of pri mary sensorimotor cortex (area 4) to this ROI is considered to be small (see Fig. lB ).] Similarly, the paracentral ROI included medial superior frontal re gions corresponding largely to the SMA !,medial area 6 or GFd (Talairach and Tournoux, 1988) ]. Thus, the reduced weights of these regions noted in Topographic Profile 1 is suggestive of diminished activity of the lateral premo tor regions and SMA. Reductions in the activity of these regions are likely to stem from overactive suppression of the ventral thalamic nuclei caused by excessive MGP inhibi tory outflow. As these cortical regions receive sub-stantial afferents from the ventral thalamus, sup pression of these thalamic nuclei is apt to reduce the metabolic activity of their motor cortical projection targets. These findings are consistent with evidence of reduced metabolism in premotor cortex in pri mate models (Palombo et aI., 1990) and PET evi dence of reduced activation of the SMA during the performance of motor tasks in PD patients (Jenkins et aI., 1992 ; Playford et aI., 1992) .
The hemispheric contrast profiles contain many of the regional elements included in Topographic Profile 1 of the bihemispheric analysis. Both signif icant contrast profiles reflect metabolic asymme tries in the thalamus covarying with asymmetries in other associated motor regions. We found that the relationship of the thalamic asymmetries with the other regional asymmetries was often of reciprocal polarity, i.e., relative increases in thalamic metab olism were associated with relative decreases in the metabolism of the covariate region. For example, in Contrast Profile 1, thalamic asymmetries were as sociated with SMA asymmetries of opposite polar ity. This reciprocal relationship is consistent with the opposite polarity of the region weights for the two structures noted in Topographic Profile 1 of the bihemispheric analysis. In Contrast Profile 2, a neg ative covariance was observed between caudate and thalamolentiform asymmetries. This may mir ror the findings of caudate and putamen hypome tabolism associated with pallidal metabolic in creases, as noted in several autoradiography studies (Kozlowski and Marshall, 1980 ; Schwartzmann et aI., 1993) .
The finding of parietal hypofunction is somewhat surprising, as this region is not associated with mo tor control systems. We interpret this finding to suggest a second locus of pathology in the PD study sample, involving brain regions implicated in the Alzheimer disease process (e.g., Foster et aI., 1984 ; Haxby et aI., 1985 ; Duara et aI., 1986) . Given the histopathological overlap between classical nigral Lewy body changes and cortical neurofibrillary tan gle pathology in postmortem specimens (Gibb, 1992) , it is reasonable that neocortical involvement may impact upon the metabolic profiles of PD pa tients, especially those with more advanced dis ease. Indeed, hypometabolism of the parietal asso ciation cortices has been reported in PD patients with dementia (Kuhl et aI., 1984; Schapiro et aI., 1993) . Our data suggest that these cortical changes may be inseparable from the parkinsonian disease process, as suggested by the high incidence of cog nitive deterioration in the PD population (Mayeux et aI., 1990) . Further investigations comparing de mented and non demented PD patients with quanti- Vol. 14, No. 5, 1994 tative neuropsychological correlations will be needed to elucidate the precise biological meaning of these metabolic changes.
The topographies of the other significant profiles extracted in this analysis have no immediate inter pretation in the framework of neuroanatomical pathways relating to motor control or the parkinso nian disease process. Furthermore, these profiles offered no simple regional reference point, such as the occipital cortex in Topographic Profile 1, by which to define topographic functional deviations. The roles of these other profiles in defining the met abolic topography of parkinsonism may be limited. Nonetheless, they may reflect shared aspects of brain function common to the different clinical groups. For example, Topographic Profile 2 was characterized by covarying topographic increases in occipital and parietal function associated with de creases in temporal lobe and midbrain function. Be cause of the commonality of this profile to both normal and disease populations, we associate this profile with the eyes-open resting state. Similarly, the relative hypofunction of the midbrain and me dial temporal areas may reflect low activity of the reticular and limbic attentional systems (Mesulam, 1981) in an unfocused non-task-driven resting state.
SSM may also identify topographic profiles shared by different disease states. We found that although PD and SND diverge in their representa tion of Topographic Profile 1, these two phenome nologically similar conditions may share other to pographic features indicative of abnormal motor system output. In this vein, it is of interest that SSF3 values, which reflect varying degrees of pre motor and supplementary motor hypofunction, may be abnormally elevated in SND, with a trend to ward elevation in severity-matched PD patients (Fig. 5C ). These results must be interpreted with caution in that they fail to achieve significance with the conservative Bonferroni correction for the three SSFs compared. Nonetheless, the regional topogra phy of this unrotated profile is neuroanatomic ally relevant in that, like Topographic Profile 1, it also reflects key elements of cortical motor output. This suggests that the between-group differences in the associated subject scores may not be due strictly to chance. With this caveat, these findings imply that SND and PD may effect their clinical manifesta tions through a common mechanism: reduced func tion of premo tor and SMA cortical efferent projec tions. Indeed, reduced activity in these cortical re gions has been suggested as the functional basis for the akinesia characterizing clinical parkinsonism (e.g., Playford et aI., 1992 ; Watts and Mandir, 1992) . Nonetheless, SMA and premotor hypofunc-tion may be the result of abnormalities in separate neural systems in different forms of parkinsonism: in PD, with primarily nigral dysfunction and lenti form hypermetabolism, through an accentuation of Topographic Profile 1; in SND, with primarily stri atal dysfunction and lentiform hypometabolism, through an accentuation of Topographic Profile 3.
Potential clinical applications
Disease Severity Assessment. We found that SSF 1 scores correlated significantly with H& Y scores and composite motor UPDRS ratings of overall disease severity, as well as with individual UPDRS ratings for rigidity and bradykinesia. The significance of these findings must be interpreted in the context of the mUltiple correlations performed between each of the seven clinical measures and numerous regional metabolic measures. Because of the close relationship between the overall severity ratings and the individual bradykinesia, rigidity, and gait ratings, these scores could not be consid ered as independent observations in the clinical metabolic correlations which were performed. We therefore chose to correct the significance levels of these correlations for the two major independent subsets of clinical scores within the motor UPDRS (i.e., bradykinesia, rigidity, and gait scores vs. tremor scores) . As in our earlier report (Eidelberg et aI., 1990) , none of the clinical correlations with the many rCMRglc and rCMRglc/GMR measures achieved significance-even without the Bonfer roni correction. This contrasts with the clinical metabolic correlations of SSF I' Correlations of this parameter with H&Y scores, composite motor scores, and individual bradykinesia and rigidity scores were all significant, even with a stringent correction for multiple regional comparisons, and were all of a similar magnitude (R 2 -30%). These significant clinical-metabolic correlations suggest that the metabolic contribution of this abnormal brain topography increases with advancing clinical disability. These results also indicate that SSF 1 val ues correlate with quantitative clinical disability with an accuracy comparable or superior to that of striatal FDOPA uptake rate constants (Eidelberg et aI., 1990; Takikawa et aI., 1994) . Because of the close intrasubject correlation between SSF 1 values and striatal FDOPA uptake rate constants (Eidel berg et aI., 1990), SSF1 calculation may provide a practical, though indirect, measure of nigrostriatal dysfunction applicable to certain clinical research situations. We have demonstrated previously that SSM techniques may be applied to individual pa tient FDG/PET data to calculate the subject score for a predetermined topographic profile . Moreover, SSM may be ap plied to sets of metabolic data acquired at different times in the course of disease to gauge progression and the effects of treatment. Thus, calculating SSF 1 values in PD patients studied longitudinally with FDG/PET can provide an additional independent metabolic measure of disease progression beyond the quantitative clinical examination. Indeed, an ac cessible metabolic parameter such as SSF 1 may be a potential alternative to FDOPA uptake as an im aging marker in longitudinal studies of disease pro gression and in assessing the effects of pharma coprotective therapies. A comprehensive compara tive study will be needed to assess the relative merits of these two PET methods as potential mark ers of the parkinsonian disease process. Early Diagnosis and Preclinical Detection. Al though the major topographic profile extracted from the analysis of bihemispheric rCMRglc data differ entiated the PD group from age-matched normals, its discriminative value is limited to PD2 patients in whom the clinical diagnosis is generally obvious. SSF 1 was not different in the normal and PD1 sub groups and did not discriminate those patients for whom differentiation from normal is clinically rele vant. Nonetheless, our data demonstrate the poten tial applicability of the topographic contrast profiles in discriminating the mildest patients (H& Y Stage I) from normals. We found that the SSFc l scores cor rectly classified all five H&Y I patients, while mis classifying only 2 of 20 normals (Fig. 3) . This degree of discrimination is comparable to that achieved with FDOPA/PET (Brooks et aI ., 1990; Takikawa et aI ., 1994) , suggesting the applicability of SSF cl mea surements in mildly affected patients in whom the clinical diagnosis is uncertain. In contrast to the H& Y I patients, the more advanced patients were not accurately discriminated from normals by SSF cl measures. Nonetheless, these patients are generally easily identified clinically and are not apt to be con fused with normals. Indeed, SSF 1 measures from bihemispheric rCMR g lc analysis may be more suit able for identifying advanced patients if additional metabolic data are needed to support the clinical diagnosis.
The topographic contrast profiles depict covary ing metabolic asymmetries of a small ma.gnitude that underlie the clinical motor asymmetry charac teristic of the early parkinsonian state. We found that the topographic representation of these asym metries includes fragments of the abnormal bilateral profile, involving primarily the lentiform nucleus, thalamus, and paracentral cortex. Additionally, the contrast profile that discriminated patients with early disease was reproducible in the prior dataset.
These topographic contrast profiles quantify inher ent metabolic asymmetries, which like clinical asymmetries, are evident in the earliest symptom atic stages of the illness (Hoehn and Yahr, 1967 ). It appears that relative lentiform hypermetabolism ap pears first contralateral to the involved hemiparkin sonian limbs, ipsilateral to the striatum, with the greater degree of presynaptic nigrostriatal dopami nergic dysfunction (Eidelberg et aI., 1990) . As nigral degeneration progresses and generalizes, the dopa minergic functioning of the opposite side also de creases, resulting in bilateral clinical involvement and concomitant bilateral metabolic changes. Thus, with the development of clinical parkinsonism, a metabolic transition appears to occur between a state of normal symmetry and a state of pathologi cal clinical and metabolic asymmetry. Contrast pro file descriptors such as SSFc 1 may therefore have utility in delineating this transition. Moreover, SSFcl calculation in individual cases may have clin ical value in confirming the diagnosis of PD in mildly affected asymmetrical patients. Addition ally, to the extent that the nigral cell loss is likely to be somewhat asymmetrical over the period of time anteceding clinical symptoms, SSF cl might have value in the preclinical identification of individuals at risk for PD on genetic or environmental grounds. Therefore, SSF C I values may provide a useful alter native to traditional FDOPA/PET methods in this regard (Brooks, 1991; Sawle, 1993) . The realistic clinical utility of the contrast profiles in early diag nosis and preclinical detection can be ascertained only through the study of more early involved pa tients and preclinical cohorts.
Dif ferential Diagnosis . It is known that up to 25% of patients clinically diagnosed in life with PD have evidence of other degenerative disorders at post mortem evaluation (Rajput, 1984; Gibb, 1992) . Al though these other conditions are pathologically heterogeneous and some are identifiable on clinical grounds by characteristic neurological signs, they are often indistinguishable from each other as well as from PD. We have used quantitative FDG/PET to characterize and differentiate some of these dis orders (Eidelberg et aI., 1991 (Eidelberg et aI., , 1993 Eidelberg, 1992; Przedborski et aI., 1993) . SND represents the akinetic-rigid disorder clinically most like PD, ac counting for 10% of the parkinsonian disorders ex amined at postmortem (Gibb, 1992) . Because SSM analyses are performed on combined clinical sam ples and are blind to patient class designations, we sought to utilize this method to explore its potential application in the differential diagnosis of clinically similar (but presumably pathologically different) neurological conditions. In the current investigation J Cereb Blood Flow Metab. Vol. 14, No.5, 1994 we used the SND population to address the follow ing questions relating to the use of SSM descriptors in differential diagnosis: (a) Did the inclusion of a third clinically discrete cohort into the SSM analy sis introduce a new topographic profile not evident in the original two-group analysis? (b) Did the in clusion of the third group alter the metabolic topog raphy of the profiles extracted from the original two-group analysis? and (c) Did any of the SSM descriptors discriminate individual SND patients from their severity-matched PD counterparts with sufficient accuracy to be useful as an imaging ad junct to the clinical examination?
In a 1 33 Xe perfusion study of mood disorder pa tients, Sackeim et aI. (1993) demonstrated that the inclusion of a AD cohort, with a distinctly different pathology, may introduce additional topographic profiles related specifically to the newly included disease type. Moreover, patients in the added co hort had altered representations of the other topo graphic profiles. In contrast, we found that the in clusion of SND patients in the SSM analysis did not create a novel SND-specific covariance profile. Our findings also indicate that the topographies of the three major covariance profiles were not altered by the inclusion of SND patients. Rather, SND and PD shared a common topographic space and differed only in topographic profile scale and orientation (i.e., SSF magnitude and sign). As expected from prior reports on lentiform hypometabolism in SND (DeVolder et aI., 1989; Eidelberg et aI., 1993) , the mean SSF 1 for this group was negative and lower than in the PD group (Fig. 5A ). We interpret these findings to suggest that SSF 1 elevations are indica tive of primarily nigral dysfunction (PD) , while SSF 1 reductions reflect predominantly striatal dys function (SND). We found that in individual patients SSF 1 con firmed the clinical diagnosis in 9 of 10 presumed SND patients and 9 of 10 age-and severity-matched clinical PD patients. Because the clinical differenti ation of the parkinsonian movement disorders is in herently imprecise, other methods of distinguishing these patients may serve as useful adjuncts to the clinical examination. Our findings suggest that SSM calculations of SSF 1 from individual FDG/PET scans may have sufficient sensitivity to enhance the accuracy of the differential diagnosis of PD and SND made solely on clinical grounds. Nonetheless, the sensitivity of SSF 1 in discriminating these clin ically similar conditions was only minima i ly supe rior to that of normalized striatal rCMRglc values or 1 8 F count rates (Eidelberg et aI., 1993) . However, differentiations based upon PET measurements in single brain regions may be complicated by poten-tial observer bias and partial volume effects (Mazzi oUa et aI., 1981) . In contrast, the use of topographic covariation profiles involving metabolic informa tion from multiple brain regions may minimize such errors. It should be noted, however, that because metabolic changes are associated with clinical pro gression in both groups, such diagnostic algorithms require control groups strictly matched for disease severity, age, and pharmacologic status. Further studies with longitudinal comparisons and postmor tem pathological confirmation are needed to ascer tain the full diagnostic potential of this technique in relation to the clinical examination.
Conclusions
In this work we demonstrate the utility of quan titative FDG/PET methods in identifying abnormal brain topographic profiles in PD and related disor ders. These topographic profiles conform to known anatomical systems associated with locomotion and to regional metabolic data from experimental ani mals models of parkinsonism. We have also dem onstrated the reproducibility of these profiles across populations and instrumentation.
Apart from their relevance to the understanding of the metabolic organization of parkinsonism, these topographic profiles have potential clinical applicability in differential diagnosis and objective disease assessment. Our results suggest further ap plications for early diagnosis and preclinical detec tion. Presently, dynamic FDOPA/PET methods serve as the best-characterized tools for addressing these clinical-research issues (Brooks et aI., 1991; Eidelberg, 1992; Sawle, 1993) . However, because of technical difficulties in implementing these meth ods, very few centers can undertake quantitative FDOPA/PET imaging on a regular basis. In con trast, FDG/PET methods are technically easier to implement in most centers and may afford compa rable data. Furthermore, to the extent that metab olism is coupled to perfusion in these disorders (Ot suka et aI., 1991) , analogous SSM approaches may be applicable to regional cerebral blood flow map ping with other imaging modalities such as single photon emission CT and functional MRI.
